Furthermore, the incidence of hemorrhagic stroke is reduced with primary balloon angioplasty. 15 The superiority of mechanical over pharmacological reperfusion points out the limited efficacy of the latter but at the same time sets a higher standard that can be achieved with respect to improved clinical outcomes. Because mechanical reperfusion is available only in specialized centers and is logistically cumbersome, a primary objective is to achieve parity between a pharmacological strategy, which is eminently more practical and universally available, and catheter-based reperfusion, if at all possible.
At present, for patient triage, a critical decision has to be made to choose between these two alternatives. The reason this has evolved is that the clinical trials that tested immediate balloon angioplasty after thrombolytic therapy all showed a higher rate of major complications compared with thrombolytic therapy alone or balloon angioplasty performed without antecedent thrombolysis. 16 -20 These trials were performed in the mid to late 1980s and have had a remarkable impact in dichotomizing the two alternative reperfusion strategies. The explanation for the phenomenon of the untoward effects of angioplasty after thrombolysis is probably the prothrombotic tendencies of fibrinolytic agents, as will be fully discussed. Virtually all of these limitations of pharmacological reperfusion therapy may be abrogated, at least in part, with newly available potent antiplatelet inhibitors. In this article, their potential to affect a radical change in our approach to myocardial reperfusion will be reviewed.
Why Thrombolysis Fails
There are many possible explanations for the observed failure in the 45% to 50% of patients who do not achieve early and complete restoration of coronary blood flow. The leading hypothesis is tied to the prothrombotic effects of thrombolytic agents coincident with a lack of a sound antiplatelet approach.
The term "thrombolytics" is a key misnomer, because this implies that these agents are capable of actually dissolving thrombus. Plasminogen activators are better known as fibrinolytics, as depicted in Fig 1, because their principal action is to lyse fibrin. When this occurs, there is exposure of thrombin and marked evidence of enhanced thrombin activity, as reflected by heightened levels of fibrinopeptide A. 21 , 22 The result of exposed thrombin is not only the autocatalytic formation of more thrombin but also the marked proaggregatory effect on platelets. Thrombin is one of the most, if not the most, potent biological activators of platelets known. The more fibrinolytic therapy is given, with lysis of fibrin clot leaving its major constituent, thrombin, as substrate, the more the prothrombotic tendency is engendered.
Platelets are at the core of a coronary thrombus, owing to their activation and adhesion to the exposed subendothelial matrix elements with plaque fissuring or rupture. 23 Although this "white clot" nidus is typically a small component relative to the "red" fibrin and erythrocyte-rich thrombus, both types are present and have been directly visualized by angioscopy. 24 The platelet thrombus is fully resistant to fibrinolytic therapy, not only on a mass basis but also because platelets are especially rich in PAI-1, the most potent naturally occurring inhibitor of fibrinolysis. Accordingly, more platelets aggregate in response to fibrinolytic therapy, and these platelets secrete PAI-1, such that a vicious circle can be set up. Moreover, our present pharmacological approach to reperfusion is void of a significant antiplatelet effect, with the first dose of aspirin administered around the time of fibrinolytic therapy. The antiaggregatory effect of aspirin on platelets, especially in the acute phase, is only modest at best. Despite this, early administration of chewable aspirin has been associated with as much mortality reduction as the use of streptokinase alone.
2 Therefore, over the past 15 years since the beginning of the reperfusion era, inadequate attention has been directed to the critical role of platelets, and the significance of the procoagulant effects of fibrinolytic agents has been underappreciated.
Other reasons for failure to achieve coronary blood reflow include the so-called "plaque disaster" as introduced by Falk et al, 23 such that there is actual mechanical obstruction in the diseased coronary artery due to frank plaque herniation into the lumen. This is a rare event, thought to occur in Ͻ5% of infarct patients. Recently, activation of the carboxypeptidase enzyme has been demonstrated by fibrinolytic agents, which may interfere with successful clot lysis, 25 but no known inhibitor is available to favorably affect this pathway. Also, inaccessibility of the clot to the plasminogen activator; aged fibrin, which is cross-linked and more tenacious; and lack of flow due to extensive myocardial tissue damage are mechanisms that have been suggested to explain the failure of reperfusion therapy.
Classic Studies
The pioneering efforts and insights provided by Willerson's group 26 -33 and Fuster et al 34, 35 have clearly laid the groundwork for a platelet-directed therapeutic strategy in acute MI. These investigations have documented the preeminent role of platelets and their dynamic responsiveness as well as release of thromboxane, serotonin, and other vasoactive amines in the setting of acute coronary syndromes. Indeed, antagonists to the thromboxane A 2 or serotonin S 2 receptors led to facilitated thrombolysis or avoidance of reocclusion of the infarct vessel in experimental models. 30, 31 Although these studies can, in retrospect, be viewed as classic, the pivotal role of platelets in this clinical setting and the potent pharmacological interventions were not fully appreciated or available until more than a decade later.
Missing the Target
The recent experience with coronary artery stenting has been instructive for routine administration of an incorrect, misguided therapy. Since coronary stenting began in 1986, there has been an empirical use of prolonged heparin and switchover to extended oral warfarin. 36 This approach led to an alarming rate of peri-access site and other serious bleeding complications, along with a prolonged hospital stay to discharge of patients with an international normalized ratio of Ն2.0.
37,38
Despite heparin and warfarin, a significant problem of subacute thrombosis was occurring in at least 3% to 4% of patients, often resulting in MI or death. Of note, aspirin was typically included in the heparin/warfarin strategy and still today is the official (package insert) Food and Drug Administration label for adjunctive pharmacological therapy after stent implantation. 39 More recently, however, clinical trials addressed the Figure 1 . Prothrombotic effects of fibrinolytic therapy. Coronary thrombus is composed of a platelet core with fibrin-thrombin admixture ("white" and "red" clot). After fibrinolytic therapy, there is exposure of free thrombin, which autocatalytically begets more thrombin and strongly promotes platelet aggregation (note more platelet mass). Platelets themselves are resistant to fibrinolytic therapy and furthermore secrete large amounts of PAI-1, which is a potent antagonist to fibrinolysis. potential strategy of a pure antiplatelet approach compared with heparin, warfarin, and aspirin. [40] [41] [42] The three trials that assessed this critical question, as summarized in Fig 2, have convincingly demonstrated the marked superiority of an enhanced antiplatelet approach over the traditional red clotdirected strategy. The combined use of aspirin and ticlopidine has subsequently radically changed the field, with a subacute thrombosis rate of Ͻ1% and no excess of bleeding complications compared with balloon angioplasty. 43 Rather than a 4-day hospital stay, patients can be discharged within 24 hours of the procedure. This valuable lesson provides the foundation and insight for a similar "missing of the target" in the therapy for patients with acute MI. What mechanistically separates these two clinical syndromes is the difference between "manmade," angioplasty-induced coronary arterial trauma versus spontaneous plaque fissuring or erosion. Otherwise, the parallels are extensive, and the possibility of a partially misguided therapy is raised.
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Emerging Role of Antiplatelet Therapy
The 1990s marked the introduction of the platelet GP IIb/IIIa inhibitors in clinical investigation and trials. 44 -53 This class of agents represents one of the most significant advances in the therapy of ischemic heart disease today. The receptor, or integrin adhesion molecule, on the surface of platelets is activated and exteriorized when platelets are stimulated. More than 50 000 to 80 000 receptors are present on each and every platelet, making this the most densely expressed component of the platelet surface. The molecular and cellular biological breakthrough was the determination that this receptor acts as the final common pathway for platelet aggregation, such that agents that block the receptor directly or compete with its primary ligand, fibrinogen, have a marked effect on inhibiting platelet-platelet interaction, ie, fully blocking aggregation.
A family of agents is now available for clinical investigation, and one agent, abciximab, a Fab antibody fragment directed against the receptor, was approved for use in percutaneous coronary intervention in early 1995. The other agents, unlike the monoclonal antibody preparation, are all competitive inhibitors and are either peptides (Integrilin) or small molecules (Tirofiban, Lamifiban, Sibrafiban, Lefradafiban, Xemilofiban, Orbofiban, and others).
Collectively, nine large clinical trials of more than 1000 patients have been performed. 44 -52 Five of these were in patients undergoing percutaneous coronary interventions, and four were conducted in patients with unstable angina or non-Q-wave MI. Viewed in aggregate, as demonstrated in Fig  3, these trials have all demonstrated benefit in the reduction of death or nonfatal MI for the combination of a GP IIb/IIIa blocker plus aspirin compared with placebo plus aspirin. The consistency between the trials is quite striking with respect to the directionality of the benefit. The magnitude has differed somewhat, with the most pronounced reduction of death and nonfatal MI achieved with the abciximab preparation. Overall, there is a highly significant 20% reduction in death or MI, which, interestingly, is similar to the extent of improvement (Ϸ25%) in the original aspirin-versus-placebo trials performed more than a decade ago. 54 Beyond the early benefit at 30 days that is presented in Fig  3, there is evidence of durability and incremental late benefit in some of the trials. For example, in the EPIC trial, the 6-month benefit for the overall cohort of 2099 patients was a sustained reduction of the composite of death, MI, and revascularization procedures. In particular, a significantly lessened need for repeat revascularization procedures was noted. 55 At 3-year follow-up of this trial, the patients who presented with acute coronary syndromes had a 60% reduction in mortality in the group assigned to abciximab bolus and infusion compared with placebo (Fig 4) . 56 Despite only a 12-hour infusion, the delayed, sustained, and in some respects incremental benefit over time after abciximab was not fully anticipated. The findings raise the hypothesis that arterial passivation was achieved, such that the intervention was capable of transforming the vessel wall surface from one that supports platelet-thrombus deposition to one that cannot do so. The findings of late benefit, manifesting well after the infusion was completed, are further corroborated by the study of Lamifiban in unstable angina and non-Q-wave MI in the PARAGON trial. 49 Whereas the 30-day relative benefit for reduced death or MI was quite modest at 9% to 10% for Lamifiban, at 6 months there was an Ϸ40% reduction for low-dose Lamifiban compared with placebo that was highly statistically significant. 49 Therefore, two distinct trials of GP 
IIb/IIIa inhibitors of different agents and clinical indications
have yielded impressive long-term results. These findings lend support to the passivation hypothesis, because it is otherwise difficult to explain further improvement in clinical outcomes at a time that is temporally dissociated from drug administration. The strong evidence of efficacy of the GP IIb/IIIa blockers has fortunately not been overshadowed by an excess of bleeding complications. Although this was raised as a concern early in the clinical trial experience, 44 the recent trials have not shown an excess of even minor bleeding complications for the GP IIb/IIIa inhibitor intervention. Most notably, in the EPILOG trial, with reduced heparin dosing on a weightadjusted basis along with limited peri-access sheath indwelling time, the bleeding events were quite infrequent and no more likely than with placebo. 45 In Table 1 , the rates of intracerebral hemorrhage for the five coronary intervention trials are provided. Of note, compared with fibrinolytic therapy, which carries an important liability for intracerebral bleeds, there has been no excess in more than 12 000 patients in clinical trials thus far. The improved safety profile of the GP IIb/IIIa inhibitors is most likely a result of preserved platelet adhesion, left intact despite fibrinogen receptor blockade, and differences in untoward hemorrhagic events as a function of the coagulation proteins vis-à-vis platelet aggregation. Still uncertain, however, is the combined use of GP IIb/IIIa inhibitors in patients receiving fibrinolytic therapy in adequate numbers (thousands) of patients to be able to provide more definitive assurance of the lack of risk of intracerebral bleeding.
Experimental Studies
Over the past decade, a substantial number of preclinical investigations of fibrinolytic therapy combined with GP IIb/ IIIa inhibitors have been carried out (summarized in Table  2) . [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] Cumulatively, these studies have shown that the dose of fibrinolytic therapy can be substantially reduced to Ϸ50% or even 25% of the dose required in control experiments 57, 58 and that fibrinolysis occurs much more rapidly and more completely and is much more stable, as reflected by the absence of cyclic flow variations or reocclusion once flow is restored. Nicolini and associates 65 showed that a low dose of a GP IIb/IIIa inhibitor combined with a low dose of a direct thrombin inhibitor (hirudin) also markedly facilitated coronary fibrinolysis in the canine electrolytic model. The demonstrated benefit has been confirmed with abciximab and other GP IIb/IIIa inhibitors such as Integrilin, Kistrin, Echistatin, and Bistatin; the latter three agents are snake venom derivatives. Owing to the concerns about bleeding complications in the face of fibrinolytic therapy, aspirin, and heparin, there was an unfortunate and substantial lag before the findings from these encouraging experimental studies led to the launch of clinical trials. 
Pilot Clinical Studies
Three studies that have combined fibrinolytic therapy and GP IIb/IIIa inhibitors are summarized in Table 3 . [72] [73] [74] The first of these, TAMI-8, tested only the murine 7E3 monoclonal antibody Fab 3 to 24 hours after t-PA was administered at full doses. 72 No simultaneous administration of the two classes of agents was assessed. Even so, the limited sample of 68 patients showed enhanced infarct vessel patency, as detected by subacute angiography, and less ST-segment oscillatory activity by continuous 12-lead ECG monitoring, suggesting reduced cyclic flow. The second trial performed, known as IMPACT-MI, 73 evaluated the combined use of full-dose, accelerated t-PA with variable dosing of Integrilin and heparin. As summarized in Table 3 , this pilot study suggested that with higher doses of Integrilin, there was improved infarct vessel patency compared with placebo. Via systematic coronary angiography, rates of TIMI 3 patency Ͼ80% were achieved at certain dose combinations, substantially better than would be expected with t-PA alone. As in the preceding trial, the digital 12-lead ECG monitoring showed faster and more stable resolution of the ST-segment elevation. A major problem in interpretation of these data is that the dose of Integrilin was subsequently shown to be inadequate owing to an in vitro artifact of previous platelet aggregation measurements. 75 Accordingly, even with doses of Integrilin that were Ϸ50% of what would be necessary to reliably achieve 80% inhibition of platelet aggregation, there were trends toward angiographic and clinical outcome improvements. Noteworthy was the lack of excess of any significant bleeding complications among the combined t-PA-and Integrilin-treated group of patients. The sample was too small, however, to make any definitive assessment of the dose combination or even an advantage over fibrinolytic therapy alone (with heparin and aspirin instead of GP IIb/IIIa blockade).
More recently, the PARADIGM trial enrolled 345 patients treated with either t-PA or streptokinase at full doses and concomitant intravenous Lamifiban (at three different doses) or placebo. 65 At higher doses of Lamifiban (such as 400 g bolus and 2.0 g/min infusion), there was an excess transfusion requirement and no clear-cut clinical outcome benefit. Although the number of patients per Lamifiban dose group was relatively small and the patients received either t-PA or streptokinase treatment, there was no trend of reducing adverse clinical outcomes such as death (at a 2.0 -g dose, 4.3% versus 1.8% for treatment versus control; at a 1.5-g dose, 0.9% and 3.3%, respectively). There was little difference in clinical reinfarction or recurrent ischemia between the treated and control patient groups. Conversely, the digital 12-lead ECG analysis extended previous experimental studies showing much more rapid ST resolution and significantly less oscillatory ST-segment fluctuation among treated patients.
The potential of sole GP IIb/IIIa inhibitor therapy as a reperfusion strategy was evaluated by Gold and colleagues 76 in both the canine model and a limited number of patients. In the preclinical studies, in which abciximab was given with heparin and aspirin, 80% achieved reperfusion. In a series of 13 patients who had angiographically confirmed occlusion of the infarctrelated artery, flow improved in 85% within 10 minutes of abciximab administration. These data indicate that abciximab, on its own, is capable of achieving coronary clot lysis in some patients, most likely as a function of active disaggregation of platelets. Although it is improbable that GP IIb/IIIa blockade alone will be sufficient in most patients, the finding that such therapy with heparin and aspirin can achieve coronary recanalization is important.
Low-Dose Fibrinolytics
The three small trials that evaluated combined therapy of GP IIb/IIIa blockade and fibrinolytics unfortunately used full doses of the latter. As discussed, it is essential to avoid higher doses of a plasminogen activator to minimize the prothrombotic effects. Furthermore, the potential for intracerebral hemorrhage and the cost of the therapy strongly support the low-dose plasminogen activator approach. Many critical questions remain, however. How low a dose can be maximally efficacious? Should this be 25% or 50% of the usual dose or some proportion in between? Which fibrinolytic is the optimal agent to combine with GP IIb/IIIa blockade? Should it be a short-acting one like t-PA, as is being assessed in the TIMI 14 trial, or a longer-acting agent given as a bolus, such as r-PA, as assessed in the GUSTO 4 pilot trial? What is the appropriate dose and duration of the GP IIb/IIIa inhibitor? Does heparin need to be administered, and if so, how much? How will such a strategy combine with catheter-based reperfusion?
Catheter-Based Reperfusion
Initial results combining primary balloon angioplasty and platelet GP IIb/IIIa blockade in the EPIC trial subgroup have been especially encouraging for a durable reduction in adverse events. 77 On the basis of these findings, a randomized trial of catheter-based reperfusion with abciximab or placebo was conducted in Ϸ500 patients with demonstration of Ͼ40% reduction in the composite of death, reinfarction, or urgent revascularization at 30 days. The use of low-dose fibrinolytic and GP IIb/IIIa blockade as an initial pharmacological strategy has the potential not only to achieve reperfusion in a high proportion of patients but also to support acute-phase intervention. Instead of confronting the prothrombotic state of fibrinolytic therapy alone, as was tested in angioplasty trials performed in the 1980s, 16 -18 such a platelet-directed strategy may promote the safety of full infarct vessel revascularization. Without the hazard of promoting coronary thrombosis or inducing serious bleeding complications, combined low-dose fibrinolytic and GP IIb/IIIa blockade has considerable potential to bridge the long-term gap between mechanical and pharmacological reperfusion therapies.
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Future Directions
A transmutation from our current approach to reperfusion to one that is "platelet-centric" is likely to occur over the next few years. Large-scale clinical trials that compare conventional fibrinolytic therapy with platelet GP IIb/IIIa inhibitors and low-dose plasminogen activator will be undertaken to validate this new approach. Ultimately, a keener appreciation of the importance and prior benign neglect of the white clot of acute coronary thrombus may be acknowledged. A highly effective pharmacological strategy that does not complicate percutaneous intervention has the potential to resolve the longstanding debate about whether to use fibrinolytic therapy or catheterbased reperfusion. Although undoubtedly the search for even more effective therapies for our most important public health problem will continue, the new plateau of reperfusion therapy would represent a significant step forward.
